Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chief Executive Officer of Ekso Bionics. "Deborah's advisory roles with the VA and the Milken Institute, combined with ...

Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Debor ...

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 st ...

Segment to appear on Fox Business News on Sunday, May 12 at 5:30 p.m. ET SAN RAFAEL, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced the Ekso Indego Personal will be featured on ‘Health Uncensored' hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Fox Business News channel on Sunday, May 12 at 5:30 p.m. ET / 2:30 p.m. PT. Scott Dav ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2024 Results Conference Call April 29, 2023 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Jason Jones - Chief Operating Officer Conference Call Participants Sean Lee - H.C. Wainwright Ben Haynor - Lake Street Operator Greetings, and welcome to the Ekso Bionics' First Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A question- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ 101 Glacier Point, Suite A San Rafael, CA 94901 (Address of principal executive offices) (Zip Code) Indicate by check mark whether the ...

[Recent Highlights and Accomplishments](index=1&type=section&id=Recent%20Highlights%20and%20Accomplishments) Ekso Bionics achieved key Q1 2024 milestones, including final CMS payment determination for Ekso Indego Personal and 29 EksoHealth unit sales - Received **final payment determination** from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal, a **key milestone** for the company's commercial strategy[3](index=3&type=chunk)[12](index=12&type=chunk) - The company's **strategic focus** is on developing the market for Indego Personal and strengthening relationships with network operators for its Enterprise devices to **drive growth**[3](index=3&type=chunk) - Sold a total of **29 EksoHealth units** during the first quarter of 2024[4](index=4&type=chunk)[12](index=12&type=chunk) [First Quarter 2024 Financial Performance](index=1&type=section&id=First%20Quarter%202024%20Financial%20Performance) Ekso Bionics reported Q1 2024 revenue of $3.8 million, improved gross margin to 52%, and reduced net loss to $3.4 million Q1 2024 vs Q1 2023 Key Financial Metrics | Metric | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | Revenue (Millions USD) | $3.8 | $4.1 | -7.3% | | Gross Profit (Millions USD) | $2.0 | $2.0 | 0% | | Gross Margin (%) | 52% | 49% | +3 p.p. | | Net Loss (Millions USD) | $3.4 | $4.4 | Improved | | Net Loss per Share (USD) | $0.20 | $0.33 | Improved | - The improvement in gross margin was primarily due to **lower EksoHealth device and service costs**[5](index=5&type=chunk) - **Operating expenses decreased**, with sales and marketing expenses falling to $1.8 million from $2.1 million due to **lower headcount**, and general and administrative expenses decreasing to $2.3 million from $3.2 million due to **reduced legal activity**, **lower headcount**, and the **absence of prior-year acquisition costs**[6](index=6&type=chunk)[7](index=7&type=chunk) [Financial Condition](index=1&type=section&id=Financial%20Condition) Ekso Bionics maintained a stable financial position as of March 31, 2024, with $8.8 million cash and reduced total liabilities Balance Sheet Highlights (as of March 31, 2024) | Metric | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and restricted cash (Millions USD) | $8.8 | $8.6 | | Total Assets (Millions USD) | $29.0 | $28.9 | | Total Liabilities (Millions USD) | $14.9 | $16.3 | | Total Stockholders' Equity (Millions USD) | $14.1 | $12.6 | [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) Detailed consolidated financial statements for Q1 2024 show Ekso Bionics' financial position with $29.0 million in assets and a $3.4 million net loss [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets were $28.96 million, with liabilities decreasing to $14.91 million and equity increasing to $14.05 million Condensed Consolidated Balance Sheets (In thousands) | | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Total current assets (Thousands USD)** | **$20,516** | **$20,208** | | Total assets (Thousands USD) | $28,957 | $28,918 | | **Total current liabilities (Thousands USD)** | **$7,312** | **$8,117** | | Total liabilities (Thousands USD) | $14,906 | $16,312 | | Total stockholders' equity (Thousands USD) | $14,051 | $12,606 | | **Total liabilities and stockholders' equity (Thousands USD)** | **$28,957** | **$28,918** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2024 operations reported $3.76 million revenue, $1.95 million gross profit, and a net loss of $3.43 million or $0.20 per share Condensed Consolidated Statements of Operations (In thousands, except per share amounts) | | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Revenue (Thousands USD) | $3,756 | $4,122 | | Gross profit (Thousands USD) | $1,951 | $2,000 | | Total operating expenses (Thousands USD) | $5,207 | $6,448 | | Loss from operations (Thousands USD) | $(3,256) | $(4,448) | | Net loss (Thousands USD) | $(3,429) | $(15,080) | | Net loss per share, basic and diluted (USD) | $(0.20) | $(0.33) |

SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding ("PDAC") contractor for the Centers for Medicare & Medicaid Services ("CMS") has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024. As previously announced ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Jason Jones - Chief Operating Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ben Haynor - Alliance Global Partners Operator Greetings, and welcome to the Ekso Bionics' Fourth Quarter 2023 Financial Results Conference Call. At this all participants’ are ...

Ekso Bionics (EKSO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this robotic exoskeleton company would post a loss of $0.31 per share when it actually produced a loss of $0.24, delivering a surprise of 22.58%.Over the last four quarters, the comp ...